ES2187521T3 - Tratamiento combinado de disminucion de hierro y de anticupero igg. - Google Patents

Tratamiento combinado de disminucion de hierro y de anticupero igg.

Info

Publication number
ES2187521T3
ES2187521T3 ES94913873T ES94913873T ES2187521T3 ES 2187521 T3 ES2187521 T3 ES 2187521T3 ES 94913873 T ES94913873 T ES 94913873T ES 94913873 T ES94913873 T ES 94913873T ES 2187521 T3 ES2187521 T3 ES 2187521T3
Authority
ES
Spain
Prior art keywords
igg
combined treatment
tumor cells
iron decrease
iron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94913873T
Other languages
English (en)
Inventor
John D Kemp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa
Original Assignee
University of Iowa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa filed Critical University of Iowa
Application granted granted Critical
Publication of ES2187521T3 publication Critical patent/ES2187521T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO PARA INHIBIR EL CRECIMIENTO DE TUMORES QUE SE COMPONE DE UNA FASE DE REDUCCION DE LOS NIVELES INTRACELULARES DE HIERRO DE LAS CELULAS TUMORALES PARA AUMENTAR LA EXPRESION DE LOS RECEPTORES DE TRANSFERRINA CELULARES EN LAS CELULAS TUMORALES Y DESPUES UNA FASE DE EXPOSICION DE LAS CELULAS TUMORALES A ANTICUERPOS DEL RECEPTOR ANTI-TRANSFERRINA IGG MONOCLONAL.
ES94913873T 1993-04-29 1994-01-25 Tratamiento combinado de disminucion de hierro y de anticupero igg. Expired - Lifetime ES2187521T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5467993A 1993-04-29 1993-04-29

Publications (1)

Publication Number Publication Date
ES2187521T3 true ES2187521T3 (es) 2003-06-16

Family

ID=21992780

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94913873T Expired - Lifetime ES2187521T3 (es) 1993-04-29 1994-01-25 Tratamiento combinado de disminucion de hierro y de anticupero igg.

Country Status (10)

Country Link
EP (1) EP0697889B1 (es)
JP (1) JPH09500868A (es)
AT (1) ATE227585T1 (es)
AU (1) AU699915B2 (es)
CA (1) CA2161656A1 (es)
DE (1) DE69431717T2 (es)
DK (1) DK0697889T3 (es)
ES (1) ES2187521T3 (es)
PT (1) PT697889E (es)
WO (1) WO1994025066A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2453892B1 (en) * 2009-07-16 2013-05-29 Institut National de la Santé et de la Recherche Medicale Pharmaceutical compositions and their use for treating cancer
WO2020127885A1 (en) * 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
CN114217071B (zh) * 2021-12-01 2023-11-14 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法铁蛋白胶乳比浊检测试剂盒

Also Published As

Publication number Publication date
DE69431717T2 (de) 2003-09-18
ATE227585T1 (de) 2002-11-15
DK0697889T3 (da) 2003-03-17
JPH09500868A (ja) 1997-01-28
PT697889E (pt) 2003-03-31
DE69431717D1 (de) 2002-12-19
AU699915B2 (en) 1998-12-17
CA2161656A1 (en) 1994-11-10
EP0697889B1 (en) 2002-11-13
EP0697889A4 (en) 1997-01-02
WO1994025066A1 (en) 1994-11-10
AU6586094A (en) 1994-11-21
EP0697889A1 (en) 1996-02-28

Similar Documents

Publication Publication Date Title
ES2131527T3 (es) Anticuerpos monoclonales contra c-kit.
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
EE03285B1 (et) Immuunsust stimuleerivad monoklonaalsed antikehad
FI912016L (fi) In vitro -menetelmä antigeenispesifisten ihmisen monoklonaalisten vasta-aineiden valmistamiseksi
EP0182467A3 (en) Human hybridoma fusion partner for production of human monoclonal antibodies
HUT72914A (en) Monoclonal, chimeric, radiolabeled antibodies to the b cell sorface antigen bp 35 ("cd20"), hybridoma cells producing monoclonal antibodies and application of antibodies for treatment of b cell lymphoma
AU4128089A (en) Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP1069185A4 (en) HUMANIZED ANTIBODY TO THE HUMAN TISSUE FACTOR (TF) AND METHOD FOR THE CONSTRUCTION OF SUCH A HUMANIZED ANTIBODY.
GR3025753T3 (en) Rapamycin assay
ES8706964A1 (es) Un procedimiento para fraccionar anticuerpos de suero.
GR3031518T3 (en) Selective system scan for multizone radiotelephone subscriber units.
ES2187521T3 (es) Tratamiento combinado de disminucion de hierro y de anticupero igg.
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
EP0759943A4 (en) MONOCLONAL ANTIBODIES SPECIFIC TO VASCULAR ENDOTHEL CELL-LIKE ENDOGLYX-1, THE ANTIQUE SELF AND ITS USE
PT733903E (pt) Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
GB2254326B (en) Monoclonal antibodies produced by in vitro immunization of lymphocytes
DE69015230D1 (de) Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung.
DE69024871D1 (de) Monoklonaler Antikörper gegen menschliches BCDF und Immuntestverfahren unter dessen Verwendung
HU9501328D0 (en) Production of human monoclonal antibodies active against hepatitis b surface antigen
ATE274920T1 (de) Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
WO1987007302A3 (en) MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
DE3689299D1 (de) Verwendung von amphipatischen Molekülen zur Radiodarstellung und Therapie mittels monoklonaler oder polyklonaler Antikörperkonjugate.
FR2621127B1 (fr) Anticorps monoclonal reconnaissant un epitope de la chaine gamma des recepteurs de surface des cellules t humaines, lignee de cellules d'hybridomes produisant cet anticorps, et utilisation de cet anticorps monoclonal